Core Viewpoint - Dong-E-E-Jiao Co., Ltd. reported a revenue increase of 11.02% year-on-year, reaching approximately 3.05 billion yuan, with a net profit of approximately 817.72 million yuan, reflecting a growth of 10.74% compared to the previous year [1][5]. Company Overview and Key Financial Indicators - The company is listed on the Shenzhen Stock Exchange under the stock code 000423, with a total of 643,976,824 shares outstanding [1]. - The profit distribution plan includes a cash dividend of 12.69 yuan per 10 shares (tax included) [1]. - Key financial metrics for the reporting period include: - Revenue: 3,050,717,291.69 yuan, up 11.02% from 2,747,957,878.26 yuan [5]. - Net profit attributable to shareholders: 817,717,365.38 yuan, up 10.74% from 738,419,138.16 yuan [5]. - Basic earnings per share: 1.2698 yuan, up 10.52% from 1.1489 yuan [5]. - Total assets: 12,782,336,803.13 yuan, down 2.33% from 13,087,136,728.33 yuan [5]. Business Operations - The company focuses on traditional Chinese medicine, particularly in the production of Ejiao (donkey-hide gelatin), which has a history of nearly 3,000 years and is recognized for its health benefits [4]. - Major products include: - Ejiao and its series, accounting for 93.24% of total revenue [8]. - Compound Ejiao syrup, which has been included in treatment guidelines for anemia related to tumors [4]. - New product lines such as "Zhuangben" and "Yanzhenqing" targeting specific health needs [4]. Competitive Advantages - The company emphasizes quality control and innovation, maintaining a 100% pass rate for product inspections and certifications [4]. - It has established a strong brand presence as a leader in the health supplement market, recognized for its commitment to quality and traditional practices [4]. - The company is actively involved in research and development, collaborating with top academic institutions to enhance product offerings and address market demands [4][6]. Financial Performance Analysis - The company experienced a significant increase in cash flow from investment activities, with a net inflow of approximately 1.11 billion yuan, a 473.91% increase year-on-year [5]. - The cash and cash equivalents rose by 32.18% to approximately 6.63 billion yuan, primarily due to the recovery of matured financial products [5][11]. - Accounts receivable increased by 133.31% to approximately 184.78 million yuan, reflecting the expansion of business operations and new product launches [5][10]. Market and Regional Performance - Revenue from the pharmaceutical industry segment was approximately 2.99 billion yuan, representing 97.88% of total revenue, with a year-on-year growth of 11.28% [8]. - The company saw varied performance across regions, with East China contributing significantly to revenue growth [8].

Group 1: Share Repurchase and Market Strategy - The company plans to continue researching share repurchase as a tool for market confidence and stock price stability, focusing on high dividend payouts as a primary investor return method [1] - The company aims to enhance brand engagement with younger consumers through product innovation and cultural initiatives, including the launch of convenient packaging and live streaming for targeted outreach [1] Group 2: Water Source Protection - The local government prioritizes the protection of the underground water source, which is rich in trace elements, ensuring high-quality and sustainable water supply through strict testing [2] Group 3: Pricing and Product Strategy - A systematic pricing governance plan is being implemented to create a sustainable pricing ecosystem for core products, transitioning from reliance on price increases to structural growth [3] - The company will dynamically adjust product prices based on supply and demand, optimizing pricing mechanisms for different consumer habits and product innovations [6] Group 4: Management and Strategic Execution - The management team will remain stable and committed to executing the "1238" strategy for steady business development [4] Group 5: Raw Material Supply Assurance - A dual-circulation raw material supply system is established, ensuring stable supply from domestic and international sources, while enhancing the utilization rate of donkey skin through research collaborations [5] Group 6: New Product Development - The company is focusing on the "Muntjac deer industry" and "Cistanche development" as new product directions, aiming for growth in high-potential segments [7]

Core Insights - A consumption trend focused on "blood nourishment" is emerging, driven primarily by young women aged 20-29, who are increasingly engaging with this market through social media platforms like Xiaohongshu and Douyin, generating billions of views and millions of discussions [1][3] Market Dynamics - The demand for blood nourishment has evolved from a functional supplement to a lifestyle ritual, leading to a diverse product matrix and innovative projects that cater to this demographic's needs [3][5] - Traditional products are being replaced by modern, aesthetically appealing alternatives, as young women prefer convenient and culturally enriched options over traditional remedies [4][5] Industry Transformation - The industry is witnessing a shift as traditional medicine companies adapt to the preferences of younger consumers, with products like "night recovery drinks" and "collagen peptide beverages" gaining popularity [5][6] - Data indicates a slow decline in overall sales in the blood nourishment market, with a projected revenue of approximately 25.85 billion yuan in 2024, down about 4% year-on-year, while specific products like donkey-hide gelatin are seeing significant growth, with some experiencing nearly 50% year-on-year increases [6] Brand Strategies - Brands are increasingly focusing on emotional value and lifestyle integration, moving away from traditional narratives to resonate with younger consumers [9][10] - Companies like Yunnan Baiyao are leveraging social media to connect with young women by addressing common health concerns and creating relatable content [10][11] Product Innovation - Brands are innovating by creating products that fit seamlessly into the daily lives of young women, such as instant herbal powders and health snacks, while also exploring cross-industry collaborations [15][16] - New entrants like Minayo are targeting the blood nourishment market with clinically validated products, emphasizing convenience and taste to appeal to younger consumers [21][22] Market Opportunities - The market for blood nourishment products is expanding, with a growing number of companies entering the space, highlighting the importance of attracting young consumers [19][23] - The health and wellness sector is showing resilience, with significant opportunities for companies to explore niche demands within the broader health market [23]

Group 1: Company Strategy and Market Position - In 2025, Dong'e Ejiao will focus on the "1238" strategy, emphasizing "growth and breakthrough" as its operational theme, and will implement the "four remakes" to enhance the entire gelatin industry chain [1] - The company holds a combined market share of 38.1% in the Qi and Xue supplement category, with Dong'e Ejiao block at 67.3% and Compound Ejiao Syrup at 31.9% [2] - Dong'e Ejiao aims to strengthen its core business and expand potential products through differentiated innovation and the establishment of technological barriers [1][2] Group 2: Financial Performance and Revenue - In Q1 2025, the company achieved online revenue of approximately 340 million yuan, a year-on-year increase of about 20% [2] - The online revenue breakdown includes: Ejiao block at approximately 120 million yuan (up nearly 15%), Compound Ejiao Syrup at approximately 60 million yuan (up nearly 60%), and Ejiao powder at approximately 60 million yuan (up nearly 50%) [2] - The overall gross margin is maintained at around 70%, with a slight increase in Q1 due to reduced costs from centralized procurement [7] Group 3: Inventory and Sales Management - The reasonable inventory level for Dong'e Ejiao block and Compound Ejiao Syrup is set at six months of terminal market sales, while for Taohua Ji Ejiao cake, it is 1.5 months [2] - The current channel inventory is at a healthy level, and terminal pure sales are progressing steadily [2] Group 4: Future Plans and Dividends - Since its first dividend in 1999, the company has distributed a total of 8.469 billion yuan over 26 occasions, with an average payout ratio of 65.75% [6] - The proposed dividend for 2024 is 818 million yuan, with a payout ratio of 99.70% [6] - The company plans to maintain a stable and proactive dividend policy based on its operational development, profitability, cash flow, and shareholder interests [6] Group 5: Challenges and Adjustments - The increase in accounts receivable in Q1 2025 is attributed to the implementation of a credit management strategy and increased procurement costs for strategic materials [4] - The company is addressing the small proportion of insurance payments for Compound Ejiao Syrup and aims for sustainable growth in this area [5]

Investment Rating - The investment rating for Dong'e Ejiao is "Buy" (maintained) [1] Core Views - The company's Q1 2025 performance met expectations, with total revenue of 1.719 billion yuan, representing a year-on-year growth of 18.24%. The net profit attributable to shareholders was 425 million yuan, up 20.25% year-on-year [9] - The company's product lines, particularly the Ejiao series, are experiencing steady growth, with various marketing strategies being employed to enhance sales and reach target demographics [9] - The company has initiated a mid-term dividend distribution, with a high dividend payout ratio of 99.7% in 2024, reflecting its commitment to returning value to shareholders [9] - The forecast for net profit attributable to shareholders for 2025-2027 is 1.864 billion, 2.215 billion, and 2.565 billion yuan respectively, with corresponding P/E ratios of 19, 16, and 14 [9] Financial Summary - Total revenue is projected to grow from 5.921 billion yuan in 2024 to 8.918 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 13.47% [1] - The net profit attributable to shareholders is expected to increase from 1.557 billion yuan in 2024 to 2.565 billion yuan in 2027, with a CAGR of approximately 15.83% [1] - The latest diluted EPS is forecasted to rise from 2.42 yuan in 2024 to 3.98 yuan in 2027 [1] - The company's return on equity (ROE) improved to 4.04% in Q1 2025, with a gross margin of 73.62% and a net profit margin of 24.73% [9]

Core Insights - The report titled "2025-2031 China Women's Health Products Industry Market Panorama Survey and Investment Potential Research Report" has been a bestseller for two consecutive years since its publication in 2024, serving as a valuable reference for companies to understand and explore the market and formulate strategic directions [1] - The report analyzes the future market trends of the women's health products industry from a macroeconomic and industrial development perspective, identifying the industry's growth potential and forecasting its future prospects [1] Industry Overview - The women's health products industry in China is segmented into eight categories: nutritional supplements (30.5%), beauty and skincare products (22.2%), weight loss products (21.2%), fatigue relief products (7.6%), sleep improvement products (7.5%), immune enhancement products (5.0%), blood sugar reduction products (3.8%), and blood lipid reduction products (2.2%) [3] - The market size of the women's health products industry in China is projected to reach 268.28 billion yuan in 2024, driven by increasing health awareness among women and rising disposable incomes [3] Supply Chain Dynamics - The upstream of the women's health products industry includes suppliers of raw materials such as traditional Chinese medicine, biological agents, plant extracts, and protein powders, with raw material costs being a significant factor affecting production costs and profit margins [6] - The downstream includes various sales channels such as pharmacies, supermarkets, specialty health stores, and e-commerce platforms, with female consumers being the primary target audience [6] Competitive Landscape - The industry features numerous participants, including domestic companies like Tongrentang, Dong'e Ejiao, and international brands like Centrum and Amway, with each company catering to different consumer needs and preferences [9] - Tongrentang leverages its rich product line and nutritional research capabilities to meet the diverse needs of women across different age groups and physiological stages [9] Future Outlook - The report provides a comprehensive analysis of the women's health products industry's development trends, competitive landscape, and strategic recommendations for companies looking to invest in this growing market [1][15] - The data in the report is sourced from authoritative institutions, industry associations, and in-depth research, ensuring accuracy and reliability for stakeholders [15][16]